Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number2
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

gemcitabine
Cisplatin
Breast Neoplasms
Salvaging
Toxicity
Stomatitis
Leukopenia
Peripheral Nervous System Diseases
Thrombocytopenia
Nausea
Vomiting
Anemia
taxane
Kidney
Safety
Survival
Liver

Keywords

  • Cisplatin
  • Gemcitabine
  • Metastatic breast cancer
  • Taxane resistant

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

@article{b613833fae184949aa45c0265e9c01d0,
title = "Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer",
abstract = "Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30{\%}) partial responses and no complete response, an overall objective response rate of 30{\%}. Median time to progression and median survival duration for all study subjects were 7 (95{\%} CI 5.1-8.9 months) and 15 months (95{\%} CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30{\%}), thrombocytopenia in 6 (18{\%}), anemia in 2 (6{\%}) and oral mucositis in 2 (6{\%}). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.",
keywords = "Cisplatin, Gemcitabine, Metastatic breast cancer, Taxane resistant",
author = "Seo, {Jae Hong} and Oh, {Sang Cheul} and Choi, {Chul Won} and Kim, {Byung Soo} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Aeree Kim and Lee, {Jae Bok} and Koo, {Bum Hwan}",
year = "2007",
month = "2",
day = "1",
doi = "10.1007/s00280-006-0266-x",
language = "English",
volume = "59",
pages = "269--274",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

AU - Seo, Jae Hong

AU - Oh, Sang Cheul

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Kim, Aeree

AU - Lee, Jae Bok

AU - Koo, Bum Hwan

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

AB - Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

KW - Cisplatin

KW - Gemcitabine

KW - Metastatic breast cancer

KW - Taxane resistant

UR - http://www.scopus.com/inward/record.url?scp=33845357272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845357272&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0266-x

DO - 10.1007/s00280-006-0266-x

M3 - Article

VL - 59

SP - 269

EP - 274

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -